908 Devices (NASDAQ:MASS) Issues Quarterly Earnings Results

908 Devices (NASDAQ:MASS) announced its quarterly earnings data on Tuesday. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.03, Zacks reports. The company had revenue of $16.07 million during the quarter, compared to analyst estimates of $15.37 million. 908 Devices had a negative net margin of 56.96% and a negative return on equity of 12.29%.

Here are the key takeaways from 908 Devices’ conference call:

• Second-quarter revenue rose 23% year over year to $16.1 million, while 198 devices were shipped and the installed base reached 4,101. U.S. state and local customers contributed more than half of quarterly revenue, supported by demand for modernized detection equipment.
• Profitability improved meaningfully, with adjusted EBITDA loss narrowing to $1.9 million from $3.9 million a year earlier and adjusted gross margin expanding to 57%. Management raised the low end of full-year 2026 revenue guidance to $68 million-$70 million, or 21%-25% growth.
• The NIRLab acquisition is gaining early traction, with more than 35 devices sold in roughly two months, each including a multiyear software subscription. Management sees cross-selling potential with MX908 and other products and aspires to increase recurring revenue from its current 31% of total revenue toward 40% over time.
• The AVCAD military program remains unresolved after its current contract ended, with the government evaluating both a continued development path and commercially available products. The company excluded AVCAD from 2026 guidance, although any contribution would be upside and management continues to view it as a potential $10 million-plus long-term opportunity.
• The company ended the quarter with $101.5 million in cash and no debt, but consumed $10.2 million during the quarter, including $13.5 million for the NIRLab acquisition. Management continues to target a mid-single-digit-million adjusted EBITDA loss for 2026 rather than breakeven.

908 Devices Trading Up 0.1%

Shares of 908 Devices stock opened at $10.02 on Thursday. The business’s 50 day simple moving average is $8.26 and its 200-day simple moving average is $7.36. The stock has a market capitalization of $378.86 million, a price-to-earnings ratio of -10.55 and a beta of 0.66. 908 Devices has a twelve month low of $5.03 and a twelve month high of $10.52.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Roth Capital increased their price target on shares of 908 Devices from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday. Wall Street Zen lowered 908 Devices from a “buy” rating to a “hold” rating in a research report on Saturday, July 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 908 Devices in a report on Friday, August 7th. Finally, Stifel Nicolaus raised their price objective on 908 Devices from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $12.50.

Insider Activity at 908 Devices

In related news, Director Christopher D. Brown sold 8,358 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $9.23, for a total transaction of $77,144.34. Following the completion of the transaction, the director owned 805,559 shares in the company, valued at $7,435,309.57. The trade was a 1.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Joseph H. Iv Griffith sold 6,940 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $9.03, for a total value of $62,668.20. Following the transaction, the chief financial officer owned 132,956 shares of the company’s stock, valued at approximately $1,200,592.68. The trade was a 4.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 106,940 shares of company stock worth $949,714. Company insiders own 28.20% of the company’s stock.

Hedge Funds Weigh In On 908 Devices

Several institutional investors have recently modified their holdings of the company. Raymond James Financial Inc. bought a new stake in 908 Devices in the 2nd quarter valued at about $48,000. Daiwa Securities Group Inc. acquired a new stake in shares of 908 Devices in the second quarter valued at approximately $61,000. PCM Encore LLC bought a new stake in shares of 908 Devices during the fourth quarter valued at approximately $62,000. The Manufacturers Life Insurance Company acquired a new position in shares of 908 Devices during the second quarter worth approximately $77,000. Finally, Walleye Capital LLC acquired a new position in shares of 908 Devices during the second quarter worth approximately $82,000. Institutional investors own 88.06% of the company’s stock.

908 Devices Company Profile

908 Devices Inc (NASDAQ: MASS) is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company’s core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.

Key products in 908 Devices’ portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.